佛慈制药：2025年前三季度制药板块毛利率为39.12%

Core Insights - The company reported a gross margin of 39.12% for its pharmaceutical segment in the first three quarters of 2025, an increase of 4.65% compared to the same period last year [2] Group 1: Financial Performance - The increase in gross margin is attributed to a decrease in the price of traditional Chinese medicine materials, which lowered production costs [2] - The company has been focusing on expanding its external market and improving internal cost efficiency [2] Group 2: Future Outlook - The company plans to further enhance market development efforts and reduce production costs to improve overall profitability and product gross margin [2]